Zimbabwe has rejected a significant American healthcare agreement valued at 367 million US dollars (£272m) spanning five years over Washington's request for confidential information.
The decision came to light following a government memo from December was disclosed, which showed President Emmerson Mnangagwa felt the agreement was "skewed".
An official representative has since clarified that the United States was demanding access to genetic material for scientific study and profit but was not willing to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for continued talks to secure a deal acceptable to both sides so the country's critical HIV treatment initiative can continue.
Broader Implications
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court halted a similar health funding agreement following concerns were raised about the safety of citizens' health data.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral deals to boost openness and accountability.
According to statements, Sixteen African countries have to date signed these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," he stated.
"Effectively, our country would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our people if a new health crisis emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one deals were upending structures previously established via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework created to manage future global health emergencies.
"This system is designed to guarantee that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to create them."
These objections over the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to further dialogue with our US partners on how subsequent co-operation might be arranged in a manner that respects the independence and interests of each country."
Health Experts Reaction
Medical experts stated it recognised the government's concerns, but urged that negotiations must proceed considering much of the nation's Aids initiatives were funded by external financing.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it commented.
The situation underscores the ongoing debate between receiving crucial international aid and safeguarding a country's data in an increasingly interconnected world.